PMC:7195088 / 14737-15641 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"653","span":{"begin":49,"end":57},"obj":"Species"},{"id":"654","span":{"begin":89,"end":97},"obj":"Species"},{"id":"732","span":{"begin":25,"end":44},"obj":"Chemical"},{"id":"733","span":{"begin":122,"end":141},"obj":"Chemical"},{"id":"734","span":{"begin":693,"end":712},"obj":"Chemical"},{"id":"906","span":{"begin":103,"end":111},"obj":"Disease"},{"id":"907","span":{"begin":537,"end":546},"obj":"Disease"}],"attributes":[{"id":"A653","pred":"tao:has_database_id","subj":"653","obj":"Tax:9606"},{"id":"A654","pred":"tao:has_database_id","subj":"654","obj":"Tax:9606"},{"id":"A732","pred":"tao:has_database_id","subj":"732","obj":"MESH:C558899"},{"id":"A733","pred":"tao:has_database_id","subj":"733","obj":"MESH:C558899"},{"id":"A734","pred":"tao:has_database_id","subj":"734","obj":"MESH:C558899"},{"id":"A906","pred":"tao:has_database_id","subj":"906","obj":"MESH:C000657245"},{"id":"A907","pred":"tao:has_database_id","subj":"907","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Open-label RCT comparing lopinavir/ritonavir (99 patients) vs. standard of care (100) in patients with COVID-19 in China. Lopinavir/ritonavir was administered at the dosage of 400/100 mg for 14 days. The primary time-to-event endpoint was clinical improvement from randomization. In the primary study population (ITT), no statistically significant differences were observed with regard to the primary endpoint of clinical improvement (HR 1.24 with standard of care as reference, 95% CI 0.90 to 1.72) and the secondary endpoint of 28-day mortality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22]"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T75","span":{"begin":103,"end":111},"obj":"Disease"}],"attributes":[{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Open-label RCT comparing lopinavir/ritonavir (99 patients) vs. standard of care (100) in patients with COVID-19 in China. Lopinavir/ritonavir was administered at the dosage of 400/100 mg for 14 days. The primary time-to-event endpoint was clinical improvement from randomization. In the primary study population (ITT), no statistically significant differences were observed with regard to the primary endpoint of clinical improvement (HR 1.24 with standard of care as reference, 95% CI 0.90 to 1.72) and the secondary endpoint of 28-day mortality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22]"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T51","span":{"begin":5,"end":10},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T52","span":{"begin":598,"end":602},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T53","span":{"begin":720,"end":721},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T54","span":{"begin":893,"end":895},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T55","span":{"begin":901,"end":903},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"}],"text":"Open-label RCT comparing lopinavir/ritonavir (99 patients) vs. standard of care (100) in patients with COVID-19 in China. Lopinavir/ritonavir was administered at the dosage of 400/100 mg for 14 days. The primary time-to-event endpoint was clinical improvement from randomization. In the primary study population (ITT), no statistically significant differences were observed with regard to the primary endpoint of clinical improvement (HR 1.24 with standard of care as reference, 95% CI 0.90 to 1.72) and the secondary endpoint of 28-day mortality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22]"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T78","span":{"begin":5,"end":10},"obj":"Chemical"},{"id":"T79","span":{"begin":25,"end":44},"obj":"Chemical"},{"id":"T80","span":{"begin":25,"end":34},"obj":"Chemical"},{"id":"T81","span":{"begin":35,"end":44},"obj":"Chemical"},{"id":"T82","span":{"begin":122,"end":131},"obj":"Chemical"},{"id":"T83","span":{"begin":132,"end":141},"obj":"Chemical"},{"id":"T84","span":{"begin":693,"end":712},"obj":"Chemical"},{"id":"T85","span":{"begin":693,"end":702},"obj":"Chemical"},{"id":"T86","span":{"begin":703,"end":712},"obj":"Chemical"}],"attributes":[{"id":"A78","pred":"chebi_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A79","pred":"chebi_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A81","pred":"chebi_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A86","pred":"chebi_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"Open-label RCT comparing lopinavir/ritonavir (99 patients) vs. standard of care (100) in patients with COVID-19 in China. Lopinavir/ritonavir was administered at the dosage of 400/100 mg for 14 days. The primary time-to-event endpoint was clinical improvement from randomization. In the primary study population (ITT), no statistically significant differences were observed with regard to the primary endpoint of clinical improvement (HR 1.24 with standard of care as reference, 95% CI 0.90 to 1.72) and the secondary endpoint of 28-day mortality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22]"}

{"project":"LitCovid-sentences","denotations":[{"id":"T92","span":{"begin":122,"end":199},"obj":"Sentence"},{"id":"T93","span":{"begin":200,"end":279},"obj":"Sentence"},{"id":"T94","span":{"begin":280,"end":668},"obj":"Sentence"},{"id":"T95","span":{"begin":669,"end":822},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Open-label RCT comparing lopinavir/ritonavir (99 patients) vs. standard of care (100) in patients with COVID-19 in China. Lopinavir/ritonavir was administered at the dosage of 400/100 mg for 14 days. The primary time-to-event endpoint was clinical improvement from randomization. In the primary study population (ITT), no statistically significant differences were observed with regard to the primary endpoint of clinical improvement (HR 1.24 with standard of care as reference, 95% CI 0.90 to 1.72) and the secondary endpoint of 28-day mortality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22]"}

{"project":"2_test","denotations":[{"id":"32360444-32187464-22369752","span":{"begin":901,"end":903},"obj":"32187464"}],"text":"Open-label RCT comparing lopinavir/ritonavir (99 patients) vs. standard of care (100) in patients with COVID-19 in China. Lopinavir/ritonavir was administered at the dosage of 400/100 mg for 14 days. The primary time-to-event endpoint was clinical improvement from randomization. In the primary study population (ITT), no statistically significant differences were observed with regard to the primary endpoint of clinical improvement (HR 1.24 with standard of care as reference, 95% CI 0.90 to 1.72) and the secondary endpoint of 28-day mortality (19.2% vs. 25.0% in investigational and comparator arms, respectively; percentage difference −5.8%, 95% CI −17.3 to 5.7). In the mITT population, lopinavir/ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care. Median time between symptoms onset and randomization was 13 days (IQR 11–16) [22]"}